Explore the impact of ICH's Q9(R1), Quality Risk Management, guideline on RBQM and clinical trials in our latest blog post. Don't miss our free infographic that simplifies this complex guideline. Enhance your risk strategies today!
Our MyRBQM Functional Service Provision model redefines FSP models in clinical trials with its unique, independent RBQM solutions. It offers integrated risk management strategies, AI-augmented tools like the MyRBQM Portal, and specialized training through the MyRBQM Academy, setting new industry standards.
In a fast-changing pharma landscape, our MyRBQM® Portal transforms clinical trial and pipeline oversight and aids in M&A due diligence, offering a strategic edge in compliance and growth.
In this blog, we explore the growing concerns about fraudulent RCTs highlighted in a recent Nature article. Discover how innovative risk management approaches can detect, prevent, and tackle these issues, facilitating more robust regulatory oversight.
How heavily do decentralized clinical trials rely on technology? We asked Craig Lipset, a leading expert in the field of decentralized clinical trials.
Discover how Decentralized Clinical Trials (DCTs) have the potential to reshape oncology care. Using our eyesON DCT Outlook, we reveal how patient demographics, broadband internet, and registered oncologists could drive DCT opportunities and potentially enhance cancer survivorship.
Be prepared for ICH E6(R3): turn guidelines into real-world action. In this post, we delve into the key updates and training gaps.
Unpacking the new ICH guidelines, E6(R3) and E8(R1), we illuminate their key elements, identify gaps, and compare the two in terms of their unity, differences, and complementarity.
Dive into the FDA's latest draft guidance on Decentralized Clinical Trials and the role of Risk-Based Quality Management. Learn how RBQM and centralized monitoring can elevate your clinical research efficiency and reliability.
Big Pharma M&As: A Worthwhile Challenge? Navigating the complex landscape of M&As in the pharmaceutical industry comes with unique objectives and potential benefits. But do these transactions truly drive shareholder value for the acquiring firm?
